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DOI 10.1016/j.chembiol.2007.11.003Cancer tumors cannot grow more than
a few millimeters in size, nor can they
spread without developing their own
network of blood vessels to supply
oxygen and nutrients. Tumor blood
vessels differ from normal blood ves-
sels in that they are chaotic, leaky, and
fragile. This difference makes them
more susceptible to compounds that
damage tumor blood vessels.
Antiangiogenic drugs such as Avas-
tin, Nexavar, and Sutent prevent new
blood vessels from forming, but a
new class of drugs, called vascular
disrupting agents or VDAs, damages
established tumor vasculature. TheseCtissue. The tumor tends to regrow. At
this point, VDAs are slated for com-
bination therapy with chemothera-
peutics and antiangiogenic drugs that
should mop up what is left of the
tumor after the VDA is administered.
‘‘All cancer therapy is a combination
of two, three, or four agents,’’ said
Kenneth Lloyd, Ph.D., Nereus chief sci-
entific officer. According to Lloyd, the
sequence of medication is key. A che-
motherapeutic is administered first and
then tumor blood vessels are knocked
out with the VDA. It is hoped that using
VDAs in combination could potentially
lower the dose of toxic chemothera-can provide options to treat cancers
resistant to conventional chemothera-
peutics.
SanDiego-basedNereusPharmaceu-
ticals (http://www.nereuspharm.com) is
one of several biotechs developing small
molecule VDAs. Nereus’s lead com-
pound NPI-2358 disrupts the tubulin
scaffolding of the endothelial cells
lining tumor blood vessel walls.
Rival compounds include OXiGENE’s
combretastatin A4 disodium phos-
phate and OXi4503 and Angiogene’s
ZD6126. Like the antiangiogenics,
VDAs are selective for tumor blood ves-
sels and spare vasculature in healthy
tissue. VDAs cut off tumor blood sup-
ply, causing the tumor to die from hyp-
oxia from the inside out. VDAs work
faster than conventional chemothera-
peutics and antiangiogenesis agents:
in a matter of hours rather than weeks.
If VDAs are administered as a sole
drug, the tumor rim remains, co-opting
blood vessels in neighboring healthy
peutics that must be administered to
do the job and produce fewer side
effects than current therapies.
Diving for Drugs
Nereus derives its anticancer com-
pounds and antibiotics from marine
microbes. According to Lloyd, marine
microbesareanunderexploitedsource
of natural products.
Fenical, an oceanographic scientist
at the Scripps Institution of Oceanog-
raphy at the University of California,
San Diego, spent two decades collect-
ing marine microorganisms. If terres-
trial organisms were rich sources of
drugs, why not ocean microbes? In
1998, Nereus was established with re-
search licensed from Scripps. The 32
person company moved to its present
laboratory in 2002.
Nereus just received $45 million in
its series D round led by BankInvest
of Copenhagen, bringing its total fund-
ing to about $100 million. Nereus is
Using VDAs, in combination, could potentially lower the
dose of toxic chemotherapeutics that must be administered
to do the job and produce fewer side effects than current
therapies.hemistry & Biology 14, November 2007 ª2backed by an international group of
venture capitalists including HBM
BioVentures, Alta Partners, Forward
Ventures, Advent International, GIMV,
InterWest Partners, and Pacific Ven-
ture Group.
The company currently has a trove
of 20,000 organisms collected from
oceans around the globe. Nereus
grows the microbes and separates the
drugs from them or synthesizes the ac-
tive compound rather than going the
DNA bioengineering route.
The company’s VDA NPI 2358 was
chosen from a series of around 200
synthetic analogs of a compound dis-
covered in an extract of Aspergillis, a
marine fungus. The compound is now
in phase I human clinical trials for solid
tumors and lymphomas. NPI 2358 is
a ‘‘second generation VDA’’ that has a
dual effect on tumor blood flow and
directly induces tumor cell apoptosis,
as does rival OXiGENE’s OXi4503.
NPI 0052, Nereus’s other lead com-
pound, a potent proteasome inhibitor,
is undergoing three phase I human
clinical trials for treatment of multiple
myeloma, solid tumors, lymphomas,
and leukemias, respectively. NPI 0052
came straight from a marine bacteria,
Salinospora tropica, that Fenical dis-
covered and Nereus inlicensed. Due
to its complex structure, the com-
pound was isolated from the bacteria
itself, which is grown in a fermentation
tank, rather than produced through
a chemical synthesis route.
According to Lloyd, the early VDAs
such as those developed by Astra
Zeneca and Aventis had side effects
such as heart attacks and stroke.
Nereus spent great effort checking
the toxicity on animals. The company
believes that the animal tests will be
a good indication of expected side ef-
fects and toxicity, since humans can
tolerate greater doses than animals.
Neureus has stiff competition from007 Elsevier Ltd All rights reserved 1199
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well as their pharma sponsors.
Combrestastins Trash Blood
Vessels,SuffocateTumorCenters
Waltham, MA-based OXiGENE’s
(http://www.oxigene.com) small mole-
cule compound Zybrestat induces
tumor blood vessels to hemorrhage,
causing tumor cells to die. OXiGENE’s
VDAs are analogs of combretastatins,
compounds isolated from the South
African tree Combretum caffrum. One
of them, CA-4 has a high affinity for tu-
bulin at or near the colchicine-binding
site, causing tubulin polymers of the
endothelial cytoskeleton to destabilize.
Drugs that target tubilin were known
to eliminate tumors in the early 1980s
when Juliana Denekamp, Ph.D., at
Gray Laboratory Cancer Research
Trust, Mount Vernon Hospital, London,
posited that damaging the neovascu-
lature in tumors was a viable strategy
for treating cancer. However, the drugs
available to her, such as vincristine,
vinblastine and colchicine, were too
toxic at the doses necessary to work.
The company has completed a
phase II study and now is enrolling pa-
tients in a registration study for Zybre-
stat as a potential treatment for ana-
plastic thyroid cancer (ATC), a rare,
fatal cancer with an incidence of about
1000–4000 cases a year in the U.S., as
well as a combination phase Ib study
of Zybrestat plus Avastin in patients
with advanced solid tumors. OXiGENE
is further conducting a phase I trial of
OXi4503, a dual-mechanism VDA in
patients with advanced solid tumors
that collapses tumor vessels and kills
tumor cells directly. OXiGENE is fo-
cusing as well on age-related macular
degeneration, ovarian cancer, and
small-cell lung cancer.
VDAs Get New Attention
All eyes now are on the deal Novartis
made with British company Antisoma
(http://www.antisoma.com) in April
2007, worth up to US $890 million, for
Antisoma’s flavinoid vascular-disrupt-
ing agent ASA404 (formerly DXMAA)
in phase II trials. DMXAA was discov-
ered by Professors Bruce Baguley and
William Denny and their teams at the
Auckland Cancer Society Research
Centre (ACSRC).1200 Chemistry & Biology 14, NovemberSanofi-aventis is developing AVE-
8062, a combrestatin A-4 analog and
microtubule-disrupting agent for tu-
mors, and plans to begin a phase III
trial in patients with advanced sar-
coma in January 2008, as well as a
second phase III trial for non-small-
cell lung cancer. The active compound
was published by Ajinomoto.
UK biotech Angiogene (http://www.
angiogene.com) reacquired the rights
to its tubulin-binding VDA, ZD6126,
from AstraZeneca after its phase I clin-
ical trial. (The company has another
VDA, MNO929, which it licensed to
San Diego-based MediciNova.) Angio-
gene is currently raising money to put
ZD6126 through phase II trials.
According to Peter Davis, Ph.D.,
Angiogene CEO, tumor angiogenesis
(the formation of blood vessels to feed
the tumor) can be driven by a number
of factors. ‘‘Because tumors are al-
ways very clever at evading therapies,
it is quite likely that a tumor is able to
escape from any therapy you give it
which is blocking one pathway,’’ ‘‘It
would be probably more effective to
actually destroy the blood vessels
already in the tumor rather than stop
new blood vessels forming.’’ While
antiangiogenics prune the vasculature
leading to the tumor to some extent, ‘‘it
is nothing like the dramatic effects we
get with vascular disrupting agents,’’
Davis said.
Rising Pressure
In the early clinical trials of a number of
VDA companies such as Angiogene,
OXiGENE, and Sanofi-aventis, hyper-
tension as well as cardiovascular side
effects appeared. ‘‘It has been a prob-
lem in the past because of its fairly
acute nature, whereas the onset of
hypertension occurs quite slowly with
antiangiogenic agents,’’ said Peter
Davis of Angiogene. ‘‘The good thing
about hypertension associated with
VDAs as opposed to antiangigenic
agents is that our hypertension only
lasts for four hours.’’ Evidence taken
from animal studies and from Angio-
gene’s competitors showed that blood
pressure could be controlled during
administration. Companies now ex-
clude patients in clinical trials for
pre-existing hypertension and cardio-
vascular problems. Davis said that2007 ª2007 Elsevier Ltd All rights reservedpatients also report tumor pain during
administration but that is now treated
by painkillers. ‘‘It is not a question of
or whether these compounds work,’’
said Davis. ‘‘They clearly do at well-tol-
erated doses. There is the question of
how best to use them in combination.’’
Mice Lit Up Like Christmas Trees
‘‘These agents (VDAs) have been
relatively successful.’’ said Dr. Robert
Kerbel, senior scientist at the Sunny-
brook Research Institute and profes-
sor in the University of Toronto’s De-
partment of Medical Biophysics and
Department of Laboratory Medicine
and Pathobiology. ‘‘There have been
hundreds and hundreds of patients;
there have been few serious adverse
events.’’ But in his angiogenesis re-
search, Kerbel was confronted with
a mystery. Why did the rim of the tumor
grow back so robustly after being
treated with VDAs, chemotherapeu-
tics, and antiangiogenic drugs? ‘‘The
only way this could possibly happen
is there must be a cell that comes
from bone marrow, which incorpo-
rates itself to become [a] full-fledged,
credentialed endothelial cell,’’ Kerbel
said. Earlier research suggested this
could not be replicated by administra-
tion of antiangiogenesis drugs. ‘‘We
tried to convince ourselves that these
CEPS (circulating endothelial progeni-
tor cells) are real. These cells exist and
they could be a surrogate biomarker
for angiogenesis.’’ Kerbel said. Kerbel,
Postdoc Yuval Skaked and team irra-
diated mice injected with GFP protein
and induced them to grow tumors.
Then they dosed them with OXiGENE’s
Zybrestat and OXi-4503. ‘‘The mice lit
up like Christmas trees,’’ Kerbel re-
counted. The team concluded that
administration of VDAs caused acute
stress, stimulating the release of CEPs
from bone marrow. ‘‘When you give
a vascular-disrupting agent, there is
a systemic response.’’ Kerbel said.
‘‘The VDAs cause a spike in CEPS.’’
‘‘Supposing after that spike occurs,
they migrate to the tumor rim, what
would they do there?’’ asked Kerbel.
‘‘They would facilitate tumor repopula-
tion.’’ But when an antiangiogenic drug
like Avastin was given in sequence be-
fore the VDA, the tumor rim size and
bloodflow were reduced [1].
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the ideal ‘‘therapeutic window,’’ cali-
brating potent drugs up to the maxi-
mum tolerated dose to kill tumors the
first time around. This kind of research
can point the way to the ideal dosage
and sequence timing of combinations.
‘‘The next major stage is how well arethese drugs working in patients.’’ Ker-
bel says. ‘‘Are they really safe? Are they
really effective?’’
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